Documents
Access a comprehensive collection of proteomics resources, including brochures, infographics, user manuals, validation data, technical notes, and white papers. Easily filter by document type, application, research area, and products to find the specific information you need.
General Terms and Conditions for Purchase of Instruments and kits for EMEA and ROW For use when purchasing kits and/or Olink® Signature Q100, or other instruments and consumables, from Olink Proteomics AB and buying entity is located outside US and North America. | ||||
General Terms and Conditions for Purchase of Instruments and Kits in Japan For use when purchasing kits and/or Signature Q100, or other instruments and consumables, from Olink Proteomics AB and buying entity is located in Japan. | ||||
General Terms and Conditions for Purchase of Instruments and Kits in North America For use when purchasing kits and/or Signature Q100, or other instruments and consumables, from Olink Proteomics Inc and buying entity is located in US or North America. | ||||
High consistency between qPCR readout instruments for Olink® data technical note | ||||
Insights from precious samples in inflammatory and infectious disease research | ||||
Insights from precious samples in metabolomic and cardiovascular disease research | ||||
Insights from precious samples in neurology research | ||||
Insights from precious samples in oncology research | ||||
Insights into cytokine storm research with circulating biomarkers (short) | ||||
Integrating Polygenic Risk Scores and Proteomics: A New Paradigm for Predicting Health Risks | ||||
Introducing Olink® Flex: Immuno-Oncology panel | ||||
Introducing Olink® Flex: Interferon Stimulation Panel | ||||
Introducing Olink® Flex: Th1/Th2/Th17 Panel | ||||
Introducing the Olink® Flex HIV-induced aging panel | ||||
Introducing the Panel Data Archive for NPX Signature | ||||
It's all relative - 4 reasons with biomarker discovery commonly uses relative quantification Absolute and relative quantification are performed in proteomics to identify and validate protein biomarkers for clinical applications. In this white paper, four reasons why relative quantification remains the prevalent method for biomarker discovery are provided. Moreover, multiplex proteomic platforms from Olink® that offer both absolute and relative quantification options are described. | ||||
Multiomics at the Frontline of Neurology Research | ||||
NovaSeq 6000 SP vs S1 flow cell comparison technical note | ||||
NovaSeq™ 6000 SP vs S4 flow cell comparison technical note | ||||
NPX Map Preprocessing |